NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Geron Corporation (GERN) Stock Analysis

Geron Corporation (GERN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

GERN

$1.16

−$0.08 (−6.45%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare GERN with… →

GERN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.24
Previous Close
$1.24
Day's Range
1.14–1.24
52-Week Range
1.04–2.01
Volume
8.91M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.61
Valuation
Market Cap
$745.27M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
29.00
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.64
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.11
Financials (FY)
Revenue (FY)
$183.88M+138.83%
Net Income (FY)
−$83.50M
Profit marginThe share of revenue left as profit after all costs and taxes.
−33.05%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
642.47M
1-Year Return
−8.66%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
9.81M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, GERN closed at $1.16, −8.66% over 1 year.

Geron Corporation (GERN) has a market capitalization of $745.27M.

In fiscal 2025, GERN reported revenue of $183.88M.

GERN Stock Return by Calendar Year

Geron Corporation (GERN) 10-year return: what $10,000 became

1 year
$10,000 $9,134
−8.66%
5 years
$10,000 $7,945
−20.55%
10 years
$10,000 $5,472
−45.28%

If you had invested $10,000 in Geron Corporation (GERN) 10 years ago, at the close on October 21, 2016, it would have been worth $5,472 at the close on October 21, 2026: −45.28% in total, −5.85% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−12.12%
2025−62.71%
2024+67.77%
2023−12.81%
2022+98.36%
2021−23.27%
2020+16.91%
2019+36.00%
2018−44.44%
2017−13.04%
2016 (partial year)−23.90%

As of October 21, 2026.

GERN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$183.88M−$83.50M−45.4%
2024$76.99M−$174.57M−226.7%
2023$237.00K−$184.13M−77,690.7%
2022$596.00K−$141.90M−23,808.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$183.88M$179.14M−$51.55M−$83.50M−45.4%
2024$76.99M$75.74M−$173.73M−$174.57M−226.7%
2023$237.00K$237.00K−$193.94M−$184.13M−77,690.7%
2022$596.00K$596.00K−$138.55M−$141.90M−23,808.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

GERN Valuation vs Biotechnology Median

Median of 608 stocks
MetricGERNBiotechnology medianvs median
P/S ratio3.6413.300.3x the median
Profit margin−33.05%−38.31%5.3 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Geron Corporation (GERN) is capitalised at $745.27M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 258.

The 52-week range on file runs from $1.04 to $2.01. The most recent close on file for GERN is $1.16, dated October 21, 2026. That is −$0.08 (−6.45%) against the previous close. The latest close sits 11.54% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $183.88M. That is +138.83% against the prior fiscal year, when revenue was $76.99M. The same year closed with a net loss of $83.50M. Profit margin runs at −33.05%. That is 5.3 percentage points above the Biotechnology median of −38.31%. Earnings per share on a trailing basis come to −0.11.

Across the 4 fiscal years on file, revenue moves from $596.00K in 2022 to $183.88M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 29. The price-to-sales ratio is 3.64. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.61. Annualized volatility over the trailing 10 years is 78.15%. The trailing one-year total return is −8.66%. Across 10 years the annualized return works out at −5.85%.

Growth & Income

The record shows no dividend for GERN.

So far in 2026 the total return is −12.12%. The strongest complete calendar year on file is 2022 at +98.36%; the weakest is 2025 at −62.71%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Geron Corporation (GERN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Geron Corporation GERN $745.27M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Geron Corporation has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Geron Corporation

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Visit website →